CJC-1295 is a development code that covers two different molecules, and the difference between them is a reactive linker called DAC. They share a backbone, they do not share a mass, and their durations differ by orders of magnitude. That one name covers both is a naming problem. Which one is in a particular vial is an analytical question, and it has a definite answer.
What the DAC is, chemically
DAC stands for Drug Affinity Complex, which describes a strategy rather than a structure. In practice it is a maleimide group joined to the peptide through a short linker. Maleimides react with free thiols, and the thiol that matters is the single unpaired cysteine on serum albumin. The two form a covalent bond by Michael addition — a reaction that needs no enzyme and no catalyst, only proximity.
The consequence is that the conjugate does not exist in the vial. What the vial holds is the unreacted precursor: a peptide carrying a linker that has not yet found a partner. Conjugation happens after administration, in the presence of albumin. This is worth stating plainly because it changes what an analytical method is looking at. A certificate for a DAC-bearing peptide describes the precursor, not the albumin adduct, and the two have very different masses.
The no-DAC form carries no linker at all. Its persistence comes from substitutions in the backbone itself, at the positions where the main degrading enzyme cuts and where the sequence is most prone to oxidation. That is a different strategy with a different ceiling: backbone substitution buys resistance, albumin binding buys residence time, and the second is much the larger effect.
Why does a blend almost always use the no-DAC form?
Because co-formulation only makes sense when the components act on comparable timescales. A growth hormone releasing peptide acting at the ghrelin receptor has a short window; pairing it with something that persists for days produces a preparation in which one component is long gone while the other is still circulating. The two mechanisms are complementary, which is the reason to combine them, but the pharmacokinetic mismatch is real. Our own co-formulated material — CJC-1295 (no DAC) with ipamorelin and CJC-1295 (no DAC) with GHRP-6 — uses the no-DAC form for exactly this reason, and the vial label says so. A blend advertised simply as "CJC-1295" without qualifying the form is withholding the one detail that determines whether the pairing is coherent. A blend fixes its ratio at manufacture, so the question cannot be corrected later by pipetting.
How to tell which form you have
Four fields can settle it, in descending order of how much they prove.
| Evidence | What it establishes | Strength |
|---|---|---|
| Molecular weight on the certificate | The linker adds several hundred daltons; the two forms cannot be confused at this resolution | Decisive |
| Sequence field, written out | Shows whether a linker is appended at all | Decisive, if present |
| Retention time on the trace | The linker is hydrophobic and shifts elution later; only comparable within one method | Suggestive |
| Product name alone | Nothing, unless the form is stated | None |
The no-DAC form has a molecular weight of 3,367.93, and a linker-bearing version sits several hundred daltons above it. That gap is enormous by the standards of mass spectrometry, which routinely resolves differences of a single dalton. There is no instrument in use that could report one and mean the other. If a certificate carries a molecular weight, the question is already answered.
Can a mass spectrum distinguish them?
Easily, and this is the cleanest case of mass spectrometry doing exactly what it is good at. The method weighs the intact molecule, the two candidates differ by a large and known increment, and no ambiguity survives. Contrast this with the harder problem the same instrument faces when two peptides share a mass but differ in residue order — there, a mass check is genuinely uninformative. Here it is conclusive. The limitation worth knowing is that a mass spectrum of the precursor says nothing about whether the maleimide is still reactive, which is a stability question rather than an identity one.
What should the certificate say?
It should name the form in the product identity field, not only in the title, and it should report a molecular weight. A document headed "CJC-1295" with a purity figure and no mass has not identified the material — it has confirmed that something was 98% of whatever it was. Identity and purity answer different questions, and purity is the one that looks informative while depending entirely on the other. For co-formulated material the identity panel has to cover both components separately, which is more work and is the reason blend certificates are longer.
Does the no-DAC form need different handling?
Its handling follows from the backbone, which contains methionine — an oxidation-prone residue — and that is the main constraint. Lyophilised and sealed at −20 °C it is stable on the timescales that matter; in solution the oxidation clock starts, which is the general case for reconstituted peptides rather than anything specific to this sequence. A linker-bearing version adds a second consideration, since a maleimide is reactive by design and will consume any free thiol it encounters, including thiol-containing buffer components. Reducing agents do not belong in the same solution.
Why the distinction is not a technicality
Two preparations that differ in duration by orders of magnitude are not interchangeable in any experiment where timing is a variable, and timing is usually a variable. Substituting one for the other changes the exposure profile completely while leaving every label, every nominal concentration and every reconstitution calculation looking identical. Nothing in the arithmetic flags it. The error surfaces as an unexplained difference between runs, and it gets attributed to almost anything before the vial.
This is the practical argument for treating the form as part of the compound's identity rather than a variant of it. The label should carry it, the certificate should confirm it, and a record that says only "CJC-1295" has recorded an ambiguity. Where a supplier cannot say which form a lot contains, that answer is itself informative.
Is "DAC-free" the same as "no DAC"?
Yes — both describe the form without the linker, as does "Modified GRF (1–29)" and its abbreviation Mod GRF (1–29). Four labels, one molecule. The naming conventions behind this are worth reading once, because the same pattern recurs across the catalogue and the ambiguity is rarely deliberate. When writing up, the sequence and the molecular weight are unambiguous in a way that no trade name is.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
